Spots Global Cancer Trial Database for ladakamycin
Every month we try and update this database with for ladakamycin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | NCT01983969 | Advanced Cancer... Lymphoma | Azacitidine Vorinostat Gemcitabine Busulfan Melphalan Dexamethasone Caphosol Glutamine Pyridoxine Rituximab | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | NCT00948064 | Leukemia | Vorinostat Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer | NCT00529022 | Solid Tumors | Azacitidine Valproic Acid Carboplatin | - | M.D. Anderson Cancer Center | |
| Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | NCT02829840 | Leukemia FLT3-Mutated Ac... FLT3-Mutated Hi... | Ponatinib 5-azacytidine Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| Azacytidine and Valproic Acid in Patients With Advanced Cancers | NCT00496444 | Advanced Cancer... | Azacitidine Valproic Acid | 2 Years - | M.D. Anderson Cancer Center | |
| Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome | NCT01254890 | Leukemia | Azacitidine Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk | NCT01720225 | Leukemia | Decitabine Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) | NCT00887068 | Leukemia AML MDS | Azacitidine | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma | NCT02701673 | Lymphoma | Busulfan Caphosol Glutamine Pyridoxine Belinostat Azacitidine Gemcitabine Melphalan Stem Cell Trans... | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) | NCT02469415 | Leukemia | Pacritinib 5-azacitidine Decitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Phase II 5-Azacytidine Plus VPA Plus ATRA | NCT00326170 | Myelodysplastic... Acute Myelogeno... | 5-Azacytidine (... Valproic Acid All-Trans Retin... | 3 Years - | M.D. Anderson Cancer Center | |
| Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML) | NCT02096042 | Leukemia | Brentuximab Ved... 5-Azacytidine | 18 Years - | M.D. Anderson Cancer Center | |
| PKC412 and 5-Azacytidine | NCT01202877 | Leukemia | 5-azacytidine PKC412 | 18 Years - | M.D. Anderson Cancer Center | |
| Azacytidine and Valproic Acid in Patients With Advanced Cancers | NCT00496444 | Advanced Cancer... | Azacitidine Valproic Acid | 2 Years - | M.D. Anderson Cancer Center | |
| Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk | NCT01720225 | Leukemia | Decitabine Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma | NCT02701673 | Lymphoma | Busulfan Caphosol Glutamine Pyridoxine Belinostat Azacitidine Gemcitabine Melphalan Stem Cell Trans... | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation | NCT02196857 | Leukemia | Azacytidine Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) | NCT02599649 | Leukemia | Lirilumab Nivolumab Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) | NCT02599649 | Leukemia | Lirilumab Nivolumab Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Azacitidine and CAPOX in Metastatic Colorectal Cancer | NCT01193517 | Colorectal Canc... | Azacitidine Capecitabine Oxaliplatin Azacitidine MTD | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS) | NCT01542684 | Leukemia | Azacytidine GM-CSF | 18 Years - | M.D. Anderson Cancer Center | |
| Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients | NCT00382590 | Acute Myelogeno... Myelodysplastic... Leukemia | 5-Azacytidine Ara-C Valproic Acid (... | 60 Years - | M.D. Anderson Cancer Center | |
| Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | NCT02829840 | Leukemia FLT3-Mutated Ac... FLT3-Mutated Hi... | Ponatinib 5-azacytidine Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome | NCT01254890 | Leukemia | Azacitidine Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer | NCT00529022 | Solid Tumors | Azacitidine Valproic Acid Carboplatin | - | M.D. Anderson Cancer Center | |
| Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) | NCT00887068 | Leukemia AML MDS | Azacitidine | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer | NCT00529022 | Solid Tumors | Azacitidine Valproic Acid Carboplatin | - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
